Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601250 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 701
- Enrollment target
NCT00601250 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 701 participants.
The verdict
NCT00601250, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 701 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control
Interventions
- DRUG linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601250
The ClinicalTrials.gov registry entry for NCT00601250 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 701 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which linagliptin is the first listed.
NCT00601250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601250 about?
NCT00601250 is a clinical study titled "Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes". The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control
What is the current status of trial NCT00601250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 701 participants. The study started on 2008-01.
What interventions are being tested in trial NCT00601250?
The interventions under investigation include: linagliptin (DRUG).
Who is sponsoring clinical trial NCT00601250?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.